125 related articles for article (PubMed ID: 15155548)
41. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.).
Guo J; Nikolic D; Chadwick LR; Pauli GF; van Breemen RB
Drug Metab Dispos; 2006 Jul; 34(7):1152-9. PubMed ID: 16611861
[TBL] [Abstract][Full Text] [Related]
42. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
[TBL] [Abstract][Full Text] [Related]
43. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
44. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.
Li T; Li N; Guo Q; Ji H; Zhao D; Xie S; Li X; Qiu Z; Han D; Chen X; You Q
Eur J Drug Metab Pharmacokinet; 2011 Dec; 36(4):249-56. PubMed ID: 21713461
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
46. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo Z; Raeissi S; White RB; Stevens JC
Drug Metab Dispos; 1997 Mar; 25(3):390-3. PubMed ID: 9172960
[TBL] [Abstract][Full Text] [Related]
47. Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes.
Ji HY; Kim SY; Kim DK; Jeong JH; Lee HS
Molecules; 2010 Sep; 15(9):6466-75. PubMed ID: 20877236
[TBL] [Abstract][Full Text] [Related]
48. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6.
Xu BQ; Ishii M; Ding LR; Fischer NE; Inaba T
Life Sci; 2003 Mar; 72(17):1953-62. PubMed ID: 12597994
[TBL] [Abstract][Full Text] [Related]
49. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Yao C; Kunze KL; Trager WF; Kharasch ED; Levy RH
Drug Metab Dispos; 2003 May; 31(5):565-71. PubMed ID: 12695344
[TBL] [Abstract][Full Text] [Related]
50. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.
Giraud C; Tran A; Rey E; Vincent J; Tréluyer JM; Pons G
Drug Metab Dispos; 2004 Nov; 32(11):1279-86. PubMed ID: 15483195
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
52. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N
Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126
[TBL] [Abstract][Full Text] [Related]
53. High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin.
Di Marco A; Cellucci A; Chaudhary A; Fonsi M; Laufer R
Drug Metab Dispos; 2007 Oct; 35(10):1737-43. PubMed ID: 17600081
[TBL] [Abstract][Full Text] [Related]
54. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
Rae JM; Soukhova NV; Flockhart DA; Desta Z
Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782
[TBL] [Abstract][Full Text] [Related]
55. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
56. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.
Birkett DJ; Rees D; Andersson T; Gonzalez FJ; Miners JO; Veronese ME
Br J Clin Pharmacol; 1994 May; 37(5):413-20. PubMed ID: 8054246
[TBL] [Abstract][Full Text] [Related]
57. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes.
He N; Xie HG; Collins X; Edeki T; Yan Z
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):813-5. PubMed ID: 16922812
[TBL] [Abstract][Full Text] [Related]
58. Identification of CYP2C19 inhibitors from phytochemicals using the recombinant human enzyme model.
Kong LM; Xu SY; Hu HH; Zhou H; Jiang HD; Yu LS; Zeng S
Pharmazie; 2014 May; 69(5):362-6. PubMed ID: 24855828
[TBL] [Abstract][Full Text] [Related]
59. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.
Jiang R; Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2013; 28(4):332-8. PubMed ID: 23318708
[TBL] [Abstract][Full Text] [Related]
60. Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes.
Jeong HU; Kong TY; Kwon SS; Hong SW; Yeon SH; Choi JH; Lee JY; Cho YY; Lee HS
Molecules; 2013 Sep; 18(9):10681-93. PubMed ID: 24005963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
